ARIAD Pharma (ARIA) Shares Continue Lower as Feuerstein Piece Highlighted

October 14, 2016 3:02 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Ariad Pharma (Nasdaq: ARIA) is reacting negatively to a week-old article on drug pricing issues posted by former Presidential candidate Bernie Sanders. Notably, biotech watcher Adam Feuerstein penned an article on the topic the prior day (Oct. 6th), specifically targeting Ariad in the piece.

With the report, Feuerstein noted that Ariad hiked the price of its leukemia drug Iclusig four times this year, with the latest being an 8 percent price hike.

Again, for the complete story, click here. Shares of Ariad are down nearly 13 percent.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Insiders' Blog, Momentum Movers, Trader Talk

Related Entities

Adam Feuerstein

Add Your Comment